Altimmune, Inc. – NASDAQ:ALT

Add to watchlist

$3.6

-4.07

-53.06%

Market closed

Open in 2 days

-2.91%

month

-2.91%

quarter

-32.42%

year

Market Cap	563.30M
Enterprise value	84.30M

P/E	-2.2
EV/Sales	-1239.73
EV/EBITDA	-0.99
Price/Sales	-2856.98
Price/Book	1.04
PEG ratio	-0.09
EPS	-1.59

Revenue	410K
EBITDA	-84.6M
Income	-92.76M
Revenue Q/Q	-76.19%
Revenue Y/Y	N/A

Profit margin	124577.94%
Oper. margin	129029.41%
Gross margin	0%
EBIT margin	129029.41%
EBITDA margin	-20634.15%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Altimmune, Inc. (NASDAQ:ALT): Profit margin
Jun 2023	6K	-16.06M	-267683.33%
Sep 2023	362K	-20.67M	-5710.22%
Dec 2023	37K	-31.64M	-85516.22%
Mar 2024	5K	-24.39M	-487880%

Altimmune Financials Estimate

Q Y

Altimmune, Inc. (NASDAQ:ALT): Analyst Estimates
Mar 2024	5K	-24.39M	-487880%
Sep 2025	1.70K	-27.84M	-1637180.36%
Dec 2025	1.17M	-19.30M	-1641.14%
Dec 2025	1.42K	-31.38M	-2208903.8%

Analysts Price target
Financials & Ratios estimates

Altimmune, Inc. (NASDAQ:ALT): Debt to assets
Jun 2023	183316000	15.60M	8.51%
Sep 2023	166573000	16.17M	9.71%
Dec 2023	210640000	16.54M	7.85%
Mar 2024	188358000	15.42M	8.19%

Altimmune, Inc. (NASDAQ:ALT): Cash Flow
Jun 2023	-19.38M	3.98M	13.24M
Sep 2023	-20.48M	4.40M	588K
Dec 2023	-16.53M	-7.95M	72.75M
Mar 2024	-16.35M	-39.52M	-261K

Altimmune alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Altimmune, Inc. (NASDAQ:ALT): Employee count
Aug 2023	52
Sep 2023	52
Oct 2023	52
Nov 2023	52
Dec 2023	52
Jan 2024	52
Feb 2024	52
Mar 2024	59
Apr 2024	59
May 2024	59
Jun 2024	59
Jul 2024	59

Altimmune
Hedge Funds Holdings Q1 2023

18.36% -76.63%

of ALT is owned by hedge funds

72 -55

hedge funds hold ALT stock

8.61M -38.20M

shares is hold by hedge funds

ALT hedge funds holdings changes

Altimmune, Inc. (NASDAQ:ALT): Insider trades (number of shares)
Period	Buy	Sel
Dec 2022	0	20000
Mar 2023	20000	0
Aug 2023	300	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	2 Feb 2024	ROBERTS M SCOT officer: Chief Sc..	Common Stock, par value $0.0001	7,775	N/A	N/A
Option	2 Feb 2024	HARRIS MATTHEW SCOTT officer: Chief Me..	Common Stock, par value $0.0001	7,775	N/A	N/A
Option	2 Feb 2024	GARG VIPIN K director, officer..	Common Stock, par value $0.0001	18,950	N/A	N/A
Option	2 Feb 2024	GARG VIPIN K director, officer..	Restricted Stock Units	18,950	N/A	N/A
Option	2 Feb 2024	ROBERTS M SCOT officer: Chief Sc..	Restricted Stock Units	7,775	N/A	N/A
Option	2 Feb 2024	HARRIS MATTHEW SCOTT officer: Chief Me..	Restricted Stock Units	7,775	N/A	N/A
Option	1 Feb 2024	ROBERTS M SCOT officer: Chief Sc..	Common Stock, par value $0.0001	6,166	N/A	N/A
Option	1 Feb 2024	ROBERTS M SCOT officer: Chief Sc..	Restricted Stock Units	6,166	N/A	N/A
Option	1 Feb 2024	HARRIS MATTHEW SCOTT officer: Chief Me..	Common Stock, par value $0.0001	6,166	N/A	N/A
Option	1 Feb 2024	HARRIS MATTHEW SCOTT officer: Chief Me..	Restricted Stock Units	6,166	N/A	N/A

Status	Patent	Filling date	Issue date
Grant	Grant Utility: Coronavirus immunogenic compositions and uses thereof Filling date: 9 Jun 2021 Issue date: 12 Jul 2022	9 Jun 2021	12 Jul 2022
Application	Application CORONAVIRUS IMMUNOGENIC COMPOSITIONS AND USES THEREOF Filling date: 9 Jun 2021 Issue date: 10 Mar 2022	9 Jun 2021	10 Mar 2022
Grant	Grant Utility: Rapid and prolonged immunologic-therapeutic Filling date: 28 Mar 2021 Issue date: 12 Oct 2021	28 Mar 2021	12 Oct 2021
Application	Application RAPID AND PROLONGED IMMUNOLOGIC-THERAPEUTIC Filling date: 28 Mar 2021 Issue date: 26 Aug 2021	28 Mar 2021	26 Aug 2021
Application	Application CORONAVIRUS IMMUNOGENIC COMPOSITIONS AND USES THEREOF Filling date: 12 Feb 2021 Issue date: 26 Aug 2021	12 Feb 2021	26 Aug 2021
Application	Application CORONAVIRUS IMMUNOGENIC COMPOSITIONS AND USES THEREOF Filling date: 12 Feb 2021 Issue date: 26 Aug 2021	12 Feb 2021	26 Aug 2021
Application	Application T-CELL INDUCING VACCINE COMPOSITION COMBINATION AND USES THEREOF Filling date: 4 Apr 2019 Issue date: 5 Aug 2021	4 Apr 2019	5 Aug 2021
Grant	Grant Utility: Rapid and prolonged immunogic therapeutic Filling date: 12 Jul 2020 Issue date: 22 Jun 2021	12 Jul 2020	22 Jun 2021
Grant	Grant Utility: Rapid and prolonged immunologic therapeutic Filling date: 11 Jul 2020 Issue date: 22 Jun 2021	11 Jul 2020	22 Jun 2021
Application	Application RAPID AND PROLONGED IMMUNOGIC THERAPEUTIC Filling date: 12 Jul 2020 Issue date: 29 Oct 2020	12 Jul 2020	29 Oct 2020

Altimmune
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 9 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 27 Mar 2024	Q4 2023 Earnings Call Transcript
Q3 2023 7 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 10 Aug 2023	Q2 2023 Earnings Call Transcript

ALT earnings call transcripts

Altimmune
Executives

Insider	Age	Compensation
Dr. Vipin K. Garg Ph.D. (1958) Pres, Chief Executive Officer & Director	67	$897,700
Dr. Matthew Scott Harris M.D., MS, FCAP, AGAF (1953) Chief Medical Officer	72	$577,190
Dr. M. Scot Roberts (1959) Chief Scientific Officer	66	$534,980

Altimmune
Latest News

Thursday, 19 December 2024
18:35	Why Altimmune Was Such a Robustly Healthy Stock on Thursday	fool.com
07:30	Altimmune Added to Nasdaq Biotechnology Index	globenewswire.com
Wednesday, 18 December 2024
16:00	ALT5 Sigma Announces Results of 2024 AGM and Corporate Update	accesswire.com
Monday, 16 December 2024
03:14	Altimmune 2025: Redefining Obesity And MASH Treatment	seekingalpha.com
Tuesday, 3 December 2024
18:04	Altimmune CEO on what's next for its experimental obesity drug	youtube.com
Monday, 2 December 2024
10:31	Altimmune Stock Up More Than 25% in a Month: Here's Why	zacks.com
Tuesday, 26 November 2024
07:30	Altimmune to Participate at Two Upcoming Investor Conferences	globenewswire.com
Friday, 15 November 2024
11:00	Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024	globenewswire.com
Wednesday, 13 November 2024
15:43	Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge	seekingalpha.com
12:38	Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health	seekingalpha.com
Tuesday, 12 November 2024
17:23	ALT5 Sigma Reports Fiscal Financial Results for Third Quarter 2024	accesswire.com
10:00	Altimmune, Inc. (ALT) Q3 2024 Earnings Call Transcript	seekingalpha.com
Monday, 11 November 2024
07:30	Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
07:30	Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer	globenewswire.com
Friday, 8 November 2024
07:46	How Altimmune Could Grab a Big Chunk of the GLP-1 Market	marketbeat.com
Thursday, 7 November 2024
07:30	Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity	globenewswire.com
Wednesday, 6 November 2024
08:30	ALT5 Sigma Welcomes FinTech Executive, Ron Pitters to Its Board of Directors	accesswire.com
07:30	Altimmune to Participate at Two Upcoming Investor Conferences	globenewswire.com
Monday, 4 November 2024
07:30	Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024	globenewswire.com
Wednesday, 23 October 2024
17:00	ALT5 Sigma to Exhibit at Money20/20 October 27-30, 2024	accesswire.com
Tuesday, 15 October 2024
08:00	Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024	globenewswire.com
Wednesday, 9 October 2024
08:30	ALT5 Sigma Reports a Record Month at Over $240 Million in Transaction Volume	accesswire.com
Wednesday, 2 October 2024
14:48	Consider Buying Potential Takeover Target Altimmune	seekingalpha.com
08:30	ALT5 Announces Plan to Separate Into Two Independent Publicly Traded Companies	accesswire.com
Tuesday, 1 October 2024
07:30	Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference	globenewswire.com
Monday, 30 September 2024
07:30	Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)	globenewswire.com
Saturday, 21 September 2024
05:21	Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects	seekingalpha.com
Thursday, 12 September 2024
11:50	Five Top Obesity Stocks to Buy and Hold Long Term	247wallst.com
Tuesday, 10 September 2024
13:09	CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes	globenewswire.com
11:00	ALT5 Sigma Reports 104% Year-Over-Year Increase in Transaction Volume to Over US$1.250 Billion for First Eight Months of 2024	accesswire.com

Ideas & Opinions

Seeking Alpha 26 Jun 2025

Altimmune: Deciphering The MASH Crash (Rating Upgrade)
Seeking Alpha 26 Jun 2025

Altimmune: FDA Path Forward Remains Despite Mixed MASH Treatment Data Of Pemvidutide
Seeking Alpha 2 Jun 2025

Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential
Seeking Alpha 29 May 2025

Altimmune: Upcoming MASH Data Could Be High Impact For Business Development Activity
Seeking Alpha 17 May 2025

In Search Of A Tailwind, Sailing The Doldrums With Madrigal Pharmaceuticals
Seeking Alpha 11 Jan 2025

Undercovered Dozen: Fannie Mae, Civitas Resources, LifeVantage, ZenaTech +
Seeking Alpha 9 Jan 2025

Fast Drug Launch For Madrigal Pharmaceuticals Brings Buyout Discussion
Seeking Alpha 30 Dec 2024

Altimmune Could Find A Partner For Its Phase 3 Exercise
Seeking Alpha 16 Dec 2024

Altimmune 2025: Redefining Obesity And MASH Treatment
Seeking Alpha 2 Jul 2024

How To Pick Top Pharma Stocks: Novo Nordisk And More

Frequently Asked Questions (FAQ)

What's the price of Altimmune stock today?

One share of Altimmune stock can currently be purchased for approximately $3.6.
When is Altimmune's next earnings date?

Unfortunately, Altimmune's (ALT) next earnings date is currently unknown.
Does Altimmune pay dividends?

No, Altimmune does not pay dividends.
How much money does Altimmune make?

Altimmune has a market capitalization of 563.30M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 726.47% to 426K US dollars.
What is Altimmune's stock symbol?

Altimmune, Inc. is traded on the NASDAQ under the ticker symbol "ALT".
What is Altimmune's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Altimmune?

Shares of Altimmune can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Altimmune's key executives?
Altimmune's management team includes the following people:
- Dr. Vipin K. Garg Ph.D. Pres, Chief Executive Officer & Director(age: 67, pay: $897,700)
- Dr. Matthew Scott Harris M.D., MS, FCAP, AGAF Chief Medical Officer(age: 72, pay: $577,190)
- Dr. M. Scot Roberts Chief Scientific Officer(age: 66, pay: $534,980)
How many employees does Altimmune have?

As Jul 2024, Altimmune employs 59 workers.
When Altimmune went public?

Altimmune, Inc. is publicly traded company for more then 8 years since IPO on 26 May 2017.
What is Altimmune's official website?

The official website for Altimmune is altimmune.com.
Where are Altimmune's headquarters?

Altimmune is headquartered at 910 Clopper Road, Gaithersburg, MD.
How can i contact Altimmune?

Altimmune's mailing address is 910 Clopper Road, Gaithersburg, MD and company can be reached via phone at +240 6541450.

Altimmune, Inc.

altimmune.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

+240 6541450

910 Clopper Road
Gaithersburg, MD 20878

CIK: 0001326190
ISIN: US02155H2004
CUSIP: 02155H200